T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy

BACKGROUND: FOLFOX-based adjuvant chemotherapy is a benefit for high-risk stage II and stage III colon cancer after curative resection. But, the prognostic factor or predictive marker for the efficacy of FOLFOX remains unclear. This study was aimed to identify the prognostic value and cumulative imp...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:World J Surg Oncol
Asıl Yazarlar: An, Min Sung, Yoo, Jong Han, Kim, Kwang Hee, Bae, Ki Beom, Choi, Chang Soo, Hwang, Jin Won, Kim, Ji Hyun, Kim, Bo Mi, Kang, Mi Seon, Oh, Min Kyung, Hong, Kwan Hee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4336700/
https://ncbi.nlm.nih.gov/pubmed/25889520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12957-015-0488-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller